Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 9/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2835317 | 1.00 | BDKRB1 (0.32) | BDKRB1ALDH1A1GAAMAPTRAPGEF4 | |
| SCHEMBL3638395 | 0.79 | BDKRB1 (0.32) | BDKRB1ALDH1A1GAAAPPHPGD | |
| SCHEMBL3635040 | 0.79 | APP (0.31) | APP | |
| SCHEMBL3638242 | 0.78 | — | — | |
| SCHEMBL3638391 | 0.78 | BDKRB1 (0.35) | BDKRB1 | |
| SCHEMBL3632444 | 0.74 | RAPGEF4 (0.35) | ALDH1A1RAPGEF4PKMSMN1; SMN2FFAR4 | |
| SCHEMBL3635954 | 0.70 | FFAR4 (0.32) | BDKRB1GAAFFAR4APP | |
| SCHEMBL2333346 | 0.68 | ALDH1A1 (0.39) | BDKRB1ALDH1A1RAPGEF4SMN1; SMN2FFAR4 | |
| SCHEMBL3441387 | 0.65 | BDKRB1 (0.38) | BDKRB1ALDH1A1GAAMAPTPKM | |
| SCHEMBL2206181 | 0.64 | BDKRB1 (0.38) | BDKRB1ALDH1A1GAAMAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8269000-B2 | Substituted pyrimidine and triazine compounds | GRUENENTHAL GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| US-20100173889-A1 | Substituted Pyrimidine and Triazine Compounds | GRUENENTHAL GMBH (DE) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173889-A1 | Substituted Pyrimidine and Triazine Compounds | ADORA2B, CCNB1, TYMS | BDKRB1 46/4885ALDH1A1 2375/4885GAA 3718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.